Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Price Target at $21.14

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have earned an average recommendation of “Moderate Buy” from the eight analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $21.14.

A number of research analysts have recently issued reports on YMAB shares. BMO Capital Markets cut their price objective on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday. Morgan Stanley dropped their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Finally, Truist Financial initiated coverage on shares of Y-mAbs Therapeutics in a report on Friday, June 28th. They issued a “buy” rating and a $21.00 price objective on the stock.

Insider Activity at Y-mAbs Therapeutics

In related news, COO Joris Wilms sold 5,000 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at approximately $449,514. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 21.50% of the stock is owned by company insiders.

Institutional Trading of Y-mAbs Therapeutics

Several large investors have recently bought and sold shares of the business. Campbell & CO Investment Adviser LLC purchased a new stake in Y-mAbs Therapeutics in the 4th quarter valued at $562,000. Ameritas Investment Partners Inc. increased its stake in Y-mAbs Therapeutics by 39.9% during the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock worth $60,000 after purchasing an additional 1,056 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Y-mAbs Therapeutics by 8.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock worth $345,000 after purchasing an additional 1,657 shares in the last quarter. Boston Partners purchased a new position in shares of Y-mAbs Therapeutics in the first quarter valued at approximately $556,000. Finally, Millennium Management LLC grew its holdings in shares of Y-mAbs Therapeutics by 23.8% in the second quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after purchasing an additional 67,233 shares in the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Trading Down 1.0 %

Shares of Y-mAbs Therapeutics stock opened at $13.27 on Friday. The firm has a market cap of $591.44 million, a PE ratio of -27.08 and a beta of 0.70. The stock has a 50 day moving average of $12.54 and a 200 day moving average of $13.61. Y-mAbs Therapeutics has a 12 month low of $4.69 and a 12 month high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. The firm had revenue of $22.80 million during the quarter, compared to analysts’ expectations of $23.09 million. During the same period last year, the company earned ($0.14) earnings per share. As a group, equities research analysts forecast that Y-mAbs Therapeutics will post -0.57 earnings per share for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.